ReviewMolecular biology research communications2026
A systematic review on the potential of modulating the IRE arm of the UPR in U87 and U251 glioblastoma cells for improved therapeutic efficacy.
Review in Molecular biology research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) remains the most aggressive primary brain tumor with poor prognosis and limited response to current therapies. Recent studies suggest that the unfolded protein response (UPR), particularly the inositol-requiring enzyme 1 (IRE1) signaling arm, plays a pivotal role in GBM pathophysiology by mediating cellular adaptation to endoplasmic reticulum stress. This systematic review evaluates the role of IRE1 in GBM cell lines (U87, U251) and investigates whether its activation or inhibition affects migration, proliferation, apoptosis, and cell death. A comprehensive search was conducted on PubMed/ Medline, Scopus, Web of Science, and Embase using various keywords up to October 14, 2025, following the PRISMA guidelines. The search aimed to identify original English-language studies that specifically examined and analyzed the IRE1 arm of the UPR pathway in glioblastoma cells. Out of 466 records, 26 studies met the inclusion criteria. Twenty studies explored IRE1 activation, while six investigated its inhibition. IRE1 activation yielded dual effects-promoting apoptosis via JNK or XBP1 pathways in some contexts, while supporting tumor survival and angiogenesis through XBP1-mediated transcription and RIDD suppression in others. Dual role of IRE1 could sensitize GBM cells to chemotherapy agents, reduced migration and proliferation, and induced apoptosis. IRE1 acts as a context-dependent regulator in GBM, showing both pro-survival and pro-death roles. Most studies report that IRE1 activation promotes glioblastoma cell death, while fewer address its inhibition. Thus, both activation and inhibition may offer therapeutic potential depending on cellular context and downstream signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.